14:37:21 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Nanexa är ett drug delivery-bolag med en egenutvecklad och patenterad drug delivery plattform PharmaShell® som används för formulering av injicerbara depåläkemedel som skapar en tillförsel av läkemedel till blodet. PharmaShell processen baseras på ALD (Atomic Layer Deposition) teknologin som innesluter läkemedelspartiklar med ett tunt skal och skapar möjlighet för läkemedelsbolag att utveckla helt nya läkemedelsprodukter. Nanexa har idag samarbete med flertalet läkemedelsbolag.

Kalender

2023-02-16 Bokslutskommuniké 2022
2022-10-25 Kvartalsrapport 2022-Q3
2022-07-21 Kvartalsrapport 2022-Q2
2022-06-09 Årsstämma 2022
2022-04-20 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-06 Kvartalsrapport 2021-Q1
2021-05-03 Ordinarie utdelning NANEXA 0.00 SEK
2021-02-18 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-03 Ordinarie utdelning NANEXA 0.00 SEK
2020-06-02 Årsstämma 2020
2020-05-15 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-12 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-06-12 Ordinarie utdelning NANEXA 0.00 SEK
2019-06-11 Årsstämma 2019
2019-05-15 Kvartalsrapport 2019-Q1
2019-02-20 Bokslutskommuniké 2018
2018-11-12 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-30 Ordinarie utdelning NANEXA 0.00 SEK
2018-05-29 Årsstämma 2018
2018-05-15 Kvartalsrapport 2018-Q1
2018-02-20 Bokslutskommuniké 2017
2017-11-10 Kvartalsrapport 2017-Q3
2017-10-23 Extra Bolagsstämma 2017
2017-08-24 Kvartalsrapport 2017-Q2
2017-06-13 Ordinarie utdelning NANEXA 0.00 SEK
2017-06-12 Årsstämma 2017
2017-05-17 Kvartalsrapport 2017-Q1
2017-02-15 Bokslutskommuniké 2016
2016-11-16 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-27 Ordinarie utdelning NANEXA 0.00 SEK
2016-05-26 Årsstämma 2016
2016-05-12 Kvartalsrapport 2016-Q1
2016-04-06 Extra Bolagsstämma 2016
2016-02-25 Bokslutskommuniké 2015
2015-11-19 Kvartalsrapport 2015-Q3
2015-08-20 Kvartalsrapport 2015-Q2
2021-11-10 08:00:00

Substantial orders and pause in the NEX-18 study

Significant events during the third quarter 2021

  • In July, Nanexa completed the fully underwritten rights issue decided in June 2021, supported by the authorisation from the Annual General Meeting, which raised SEK 107 million after issue costs for the company.
  • The European Patent Office (EPO) announced in July its intention to grant a European patent for Nanexa's PharmaShell® technology.
  • Nanexa received two orders for the surface treatment of a large number of sensors for the detection of radioactive isotopes of the noble gas xenon, from two US customers for a total value of approximately SEK 1.7 million.
  • Nanexa decided at the end of September to pause the inclusion of patients in the company's Phase I trial of NEX-18, a depot formulation of 5-azacitidine, due to moderate skin reactions at the injection site. An investigation into the cause was initiated with the clinics participating in the study.

Significant events after the end of the period

  • Nanexa received a decision from the Swedish Financial Supervisory Authority to pay a penalty of SEK 1,000,000 in relation to an incident that occurred in 2017.
  • Nanexa signed an additional Material Transfer and Feasibility Study Agreement with one of its existing customers for the evaluation of the PharmaShell® technology with a specific biological drug substance.
  • Additional preclinical studies were initiated in October to investigate the cause of the moderate skin reactions seen in the company's Phase I study of NEX-18, a depot formulation of 5-azacitidine.

Summary of the reporting period 1 July – 30 September 2021

  • Turnover amounted to: TSEK 826 (530)
  • Operating profit (EBIT) amounted to: TSEK -7,857 (-3,814)
  • Profit after tax amounted to: TSEK -7,904 (-3,894)
  • Earnings per share amounted to: SEK -0.18 (-0.18)
  • Cash flow for the period amounted to: TSEK 91,203 (-8,098)
  • Cash and cash equivalents at end of period: TSEK 119,799 (25,990)

Summary of the reporting period 1 January – 30 September 2021

  • Turnover amounted to: TSEK 1,704 (1,819)
  • Operating profit (EBIT) amounted to: TSEK -22,776 (-13,713)
  • Profit after tax amounted to: TSEK -22,912 (-13,914)
  • Earnings per share amounted to: SEK -0.75 (-0.71)
  • Cash flow for the period amounted to: TSEK 107,108 (14,612)
  • Cash and cash equivalents at end of period: TSEK 119,799 (25,990)

Figures in brackets refer to the corresponding period in the previous year.